You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 16, 2025

Details for Patent: 10,005,783


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,005,783
Title:Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Inventor(s): Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Boulder, CO)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:15/399,389
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,005,783: A Detailed Analysis of Scope and Claims

Introduction

The United States Patent 10,005,783, titled "Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds," is a significant patent in the pharmaceutical sector, particularly in the treatment of various diseases. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Publication Number and Authority

The patent, numbered US10,005,783B2, was granted by the United States Patent and Trademark Office (USPTO)[4].

Prior Art and Background

The patent involves compounds useful in the synthesis of treatments for pain, cancer, inflammation, neurodegenerative diseases, and Trypanosoma cruzi infection. The background section of the patent highlights the need for effective treatments for these conditions and the limitations of existing therapies.

Claim Structure

The patent includes multiple claims that define the scope of the invention. Here are some key aspects:

Independent Claims

  • The patent includes independent claims that describe the specific compounds and their uses. For example, Claim 1 defines a compound with a specific chemical structure and its application in treating diseases[4].

Dependent Claims

  • Dependent claims further specify the invention by detailing particular aspects of the compounds, such as specific substituents, dosages, and methods of administration.

Scope of the Patent

Chemical Compounds

The patent focuses on substituted pyrazolo[1,5-a] pyrimidine compounds. These compounds are described in detail, including their chemical structures and the methods for their synthesis. The scope includes various derivatives and analogs of these compounds, which are useful in treating a range of diseases[4].

Therapeutic Applications

The patent covers the use of these compounds in treating several diseases, including:

  • Cancer: Specifically, breast cancer, neuroblastoma, glioma, and other types of tumors.
  • Pain: The compounds are indicated for the treatment of pain, which can be associated with various conditions.
  • Inflammation: Anti-inflammatory properties of the compounds are highlighted.
  • Neurodegenerative Diseases: The patent mentions the potential use in treating neurodegenerative diseases.
  • Trypanosoma cruzi Infection: The compounds are also useful in treating infections caused by this parasite[4].

Claim Analysis

Claim Language and Metrics

The claim language is crucial in defining the patent scope. Metrics such as independent claim length and independent claim count can be used to measure patent scope. Research suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Specific Claims

  • Claim 1: Defines the core compound and its therapeutic use.
  • Dependent Claims: Specify various aspects such as dosage forms (e.g., tablets, syrups), methods of administration, and specific disease targets.

Patent Landscape

Related Patents and Applications

The patent landscape includes other patents and applications related to pyrazolo[1,5-a] pyrimidine compounds. For instance, other patents may cover similar compounds or different therapeutic applications. The Global Dossier service provided by the USPTO can help identify related applications and their status across different IP offices[1].

Prior Art and Citations

The patent cites prior art related to the synthesis and therapeutic use of similar compounds. The Common Citation Document (CCD) application can provide a consolidated view of prior art citations from multiple IP offices, helping to understand the broader context of the invention[1].

Search and Examination Process

Tools and Resources

The USPTO provides several tools and resources for searching and examining patents, including the Patent Public Search tool, Global Dossier, and the Patent Examination Data System (PEDS). These tools can help in understanding the patent's position within the existing body of prior art[1].

Examination Data

The PEDS system allows users to search, view, and download bibliographic data for patent applications, including those related to this patent. This can provide insights into the examination process and any office actions that may have been taken[1].

Legal and Policy Considerations

Patent Quality and Scope

The debate on patent quality and scope is relevant here. The patent's claims must be clear, specific, and not overly broad to avoid issues of validity and litigation. Research indicates that narrower claims are often associated with higher grant rates and shorter examination times[3].

Potential for Litigation

The scope and claims of the patent can impact its vulnerability to litigation. A well-defined scope helps in avoiding disputes over patent infringement and validity. The study on small claims patent courts highlights the need for efficient mechanisms to resolve patent disputes, which could affect patents like this one[2].

Key Takeaways

  • Specific Compounds: The patent focuses on substituted pyrazolo[1,5-a] pyrimidine compounds.
  • Therapeutic Applications: Covers treatments for cancer, pain, inflammation, neurodegenerative diseases, and Trypanosoma cruzi infection.
  • Claim Structure: Includes independent and dependent claims defining the scope of the invention.
  • Patent Landscape: Part of a broader landscape of related patents and applications.
  • Search and Examination: Utilizes USPTO tools like Patent Public Search and PEDS.
  • Legal Considerations: Narrow claims are crucial for patent quality and avoiding litigation.

FAQs

Q: What is the main subject of United States Patent 10,005,783?

A: The patent covers methods of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds.

Q: What diseases are targeted by the compounds described in the patent?

A: The compounds are useful in treating cancer, pain, inflammation, neurodegenerative diseases, and Trypanosoma cruzi infection.

Q: How can one search for related patents and applications?

A: The USPTO's Patent Public Search tool and the Global Dossier service can be used to identify related applications.

Q: What metrics can be used to measure the scope of a patent?

A: Metrics such as independent claim length and independent claim count can be used to measure patent scope.

Q: Why are narrower claims important in patent applications?

A: Narrower claims are associated with higher grant rates, shorter examination times, and reduced litigation risks.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. Google Patents - US10005783B2: https://patents.google.com/patent/US10005783B2/en

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,005,783

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ⤷  Try for Free
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ⤷  Try for Free
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,005,783

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3106463 ⤷  Try for Free 301033 Netherlands ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free PA2020504 Lithuania ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free CA 2020 00013 Denmark ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free 122020000012 Germany ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free LUC00150 Luxembourg ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free 2020C/507 Belgium ⤷  Try for Free
European Patent Office 3106463 ⤷  Try for Free CR 2020 00013 Denmark ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.